1. Home
  2. MXL vs IMVT Comparison

MXL vs IMVT Comparison

Compare MXL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$91.97

Market Cap

8.5B

Sector

Technology

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$38.87

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
IMVT
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.0B
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
MXL
IMVT
Price
$91.97
$38.87
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$41.67
$33.00
AVG Volume (30 Days)
3.3M
1.4M
Earning Date
04-23-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
N/A
EPS
N/A
N/A
Revenue
$478,596,000.00
N/A
Revenue This Year
$22.10
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.77
$14.32
52 Week High
$128.30
$41.23

Technical Indicators

Market Signals
Indicator
MXL
IMVT
Relative Strength Index (RSI) 50.24 60.24
Support Level $74.01 $25.13
Resistance Level $105.27 N/A
Average True Range (ATR) 11.69 1.31
MACD -1.63 -0.18
Stochastic Oscillator 27.41 34.95

Price Performance

Historical Comparison
MXL
IMVT

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: